FDA says Avastin should no longer be used for breast cancer, Genentech plans appeal
This article was originally published in Scrip
Executive Summary
Genentech's top-selling anticancer drug Avastin (bevacizumab) should no longer be marketed for the treatment of metastatic breast cancer, the FDA has said in rare and controversial decision to withdraw its accelerated marketing approval of a drug, which follows the recommendation of its advisory committee.